急性进展性缺血性脑卒中血管内治疗的疗效分析

Efficacy analysis of endovascular treatment for acute progressive ischemic stroke

目的探讨急性进展性缺血性脑卒中血管内治疗的临床疗效。方法选取脑卒中患者共44例,其中血管内治疗组21例,药物治疗组23例。记录两组入院时美国国立卫生研究院卒中量表(NIHSS)评分,病情进展后NIHSS评分,手术后或药物治疗后3 d NIHSS评分以及发病90 d NIHSS评分和改良Rankin量表(m RS)评分。采用t检验分析对比两组数据之间的差异。结果血管内治疗组与药物治疗组相比较,入院时NIHSS评分分别为(3.8±2.1)分与(4.8±1.1)分,病情进展后分别为(19.8±4.1)分与(21.8±3.1)分,差异无统计学意义。手术后或药物治疗后3 d NIHSS评分分别为(9.8±3.1)分与(25.8±5.1)分,比较差异有统计学意义(P<0.01)。发病90 d NIHSS评分分别为(5.0±1.6)分与(14.8±3.7)分,比较差异有统计学意义(P<0.01);m RS评分分别为(2.0±0.5)分与(4.3±0.4)分,比较差异有统计学意义(P<0.05)。结论血管内治疗是治疗急性进展性缺血性卒中的一种有效的方法,能够在一定程度上减轻患者肢体残疾水平和改善生活质量。

Objective To explore efficacy analysis of endovascular treatment for acute progressive ischemic stroke. Methods The clinical data of 44 patients with acute progressive ischemic stroke treated in hospital were analyzed. Of them, 21 patients were in the endovascular treatment group and 23 patients were in the drug treatment group. The NIHSS scores and m RS scores of two groups of patients were recorded at different periods. Results NIHSS score was 3.8±2.1 and 4.8±1.1 on admission and 19.8±4.1 and 21.8±3.1 at the time of progression, respectively. There was no statistically significant difference between the endovascular treatment group and the drug treatment group. There was significant difference in the score of 9.8±3.1 and 25.8±5.1 at three days after operation or drug treatment(P<0.01). There was significant difference between NIHSS score of 5.0±1.6 and 14.8±3.7 for two groups at 90 days after onset(P<0.01). There was significant difference between 2.0±0.5 and 4.3±0.4 in m RS score(P<0.05). Conclusions Endovascular treatment for acute progressive ischemic stroke is feasible. To some extent, it can reduce disability of patients and improve the quality of life.